BioLineRx Ltd (NASDAQ:BLRX) shares were flat in Wednesday trading. BioLineRx shares climbed 53% on Tuesday after the company announced positive top-line results from the GENESIS Phase 3 trial evaluating its lead clinical candidate, Motixafortide, in combination with granulocyte colony stimulating factor, the standard-of-care, for hematopoietic stem-cell mobilization for autologous bone marrow transplantation in multiple myeloma patients.
In mid-April, the Israeli-based company presented a poster at the AACR Annual Meeting.
The poster, entitled: "A Multi-Center Phase 2a Trial of the CXCR4 inhibitor Motixafortide (BL-8040) in Combination with Pembrolizumab and Chemotherapy, in Patients with Metastatic Pancreatic Adenocarcinoma, the COMBAT Study," included new analyses from the Company's Phase 2a COMBAT/KEYNOTE-202 triple combination study of motixafortide in metastatic pancreatic cancer, further detailing the clinical effect of the combination in patients with and without liver metastases.
The COMBAT/KEYNOTE-202 study evaluated BioLineRx's lead clinical candidate, motixafortide, in combination with KEYTRUDA ® and chemotherapy in patients with advanced pancreatic ductal adenocarcinoma, or PDAC. Top-line results from the study were announced in December 2020 .
"Liver metastases are a critical factor driving poor prognoses for patients with metastatic PDAC," stated Dr. Abi Vainstein, Chief Medical Officer of BioLineRx.
"We are very pleased to present this additional analysis, which further strengthens the results reported from the COMBAT/KEYNOTE-202 trial in December 2020, since not only were substantially all patients initially diagnosed with stage 4 disease, but the vast majority (~80%) of the patients had liver metastases, emphasizing the extremely difficult patient population in this study."
BLRX shares lost six cents, or 1.2%, to $4.82.
